X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Veneno will conduct a program to obtain functional peptides (DRPs) for ion channels targeted by Sumitomo Pharma using Veneno Technologies' next-generation peptide discovery technology, the PERISS™ method (intra-periplasm secretion and selection).
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Peptide
Partner/Sponsor/Collaborator: Sumitomo Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 18, 2023
Details:
Under the agreement, Veneno will conduct a program to obtain functional peptides (DRPs) for G protein-coupled receptors (GPCRs) targeted by Astellas using Veneno's next-generation peptide discovery technology, the PERISS method (intra-periplasm secretion and selection).
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Peptide
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 10, 2023
Details:
The funds raised will be used to strengthen the recruitment and organizational structure of the Company's proprietary peptide drug discovery platform technology, and invest in the research and development of drug discovery pipeline of natural DRPs (Disulfide Rich Peptides).
Lead Product(s): Disulfide Rich Peptides
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Peptide
Partner/Sponsor/Collaborator: SBI Investment Co
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
